1. The amyloid beta 42/38 ratio as a plasma biomarker of early memory deficits in cognitively unimpaired older adults.
- Author
-
Bamford AR, Adams JN, Kim S, McMillan LC, Malhas R, Mapstone M, Hitt BD, Yassa MA, and Thomas EA
- Subjects
- Humans, Male, Female, Aged, Aged, 80 and over, Alzheimer Disease blood, Alzheimer Disease diagnosis, Alzheimer Disease diagnostic imaging, Cognition physiology, Brain diagnostic imaging, Brain metabolism, Memory, Learning physiology, Amyloid beta-Peptides blood, Biomarkers blood, Memory Disorders blood, Memory Disorders etiology, Memory Disorders diagnosis, Peptide Fragments blood, Positron-Emission Tomography
- Abstract
The amyloid beta (Aβ) 42/40 ratio has been widely studied as a biomarker in Alzheimer's disease (AD); however, other Aβ peptides could also represent relevant biomarkers. We measured levels of Aβ38/40/42 in plasma samples from cognitively-unimpaired older adults and determined the relationships between Aβ levels and amyloid positron-emission-tomography (PET) and performance on a learning and memory task. We found that all Aβ peptides individually and the Aβ42/40 ratio, but not the Aβ42/38 ratio, were significantly correlated with brain amyloid (Aβ-PET). Multiple linear modeling, adjusting for age, sex, education, APOE4 and Aβ-PET showed significant associations between the Aβ42/38 ratio and memory. Further, associations between the Aβ42/38 ratio and learning scores were stronger in males and in Aβ-PET-negative individuals. In contrast, no significant associations were detected between the Aβ42/40 ratio and any learning measure. These studies implicate the Aβ42/38 ratio as a biomarker to assess early memory deficits and underscore the utility of the Aβ38 fragment as an important biomarker in the AD field., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF